Literature DB >> 14724640

Immune recognition of a human renal cancer antigen through post-translational protein splicing.

Ken-Ichi Hanada1, Jonathan W Yewdell, James C Yang.   

Abstract

Cytotoxic T lymphocytes (CTLs) detect and destroy cells displaying class I molecules of the major histocompatibility complex (MHC) that present oligopeptides derived from aberrant self or foreign proteins. Most class I peptide ligands are created from proteins that are degraded by proteasomes and transported, by the transporter associated with antigen processing, from the cytosol into the endoplasmic reticulum, where peptides bind MHC class I molecules and are conveyed to the cell surface. C2 CTLs, cloned from human CTLs infiltrating a renal cell carcinoma, kill cancer cells overexpressing fibroblast growth factor-5 (FGF-5). Here we show that C2 cells recognize human leukocyte antigen-A3 MHC class I molecules presenting a nine-residue FGF-5 peptide generated by protein splicing. This process, previously described strictly in plants and unicellular organisms, entails post-translational excision of a polypeptide segment followed by ligation of the newly liberated carboxy-terminal and amino-terminal residues. The occurrence of protein splicing in vertebrates has important implications for the complexity of the vertebrate proteome and for the immune recognition of self and foreign peptides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724640     DOI: 10.1038/nature02240

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  103 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Discriminating self from nonself with short peptides from large proteomes.

Authors:  Nigel J Burroughs; Rob J de Boer; Can Keşmir
Journal:  Immunogenetics       Date:  2004-07-30       Impact factor: 2.846

Review 3.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 4.  Database of T cell-defined human tumor antigens: the 2013 update.

Authors:  Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Cancer Immun       Date:  2013-07-15

5.  Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Hugo D Meiring; Lennert Janssen; Jacques J Neefjes; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

Review 6.  HIPs and HIP-reactive T cells.

Authors:  T A Wiles; T Delong
Journal:  Clin Exp Immunol       Date:  2019-06-17       Impact factor: 4.330

7.  Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Jan A J Geenevasen; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

Review 8.  Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.

Authors:  Ken-ichi Hanada; James C Yang
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

9.  De novo peptide sequencing using exhaustive enumeration of peptide composition.

Authors:  Matthew T Olson; Jonathan A Epstein; Alfred L Yergey
Journal:  J Am Soc Mass Spectrom       Date:  2006-06-02       Impact factor: 3.109

10.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.